- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03189355
Expression of Protein Tyrosine Phosphatase 1B (PTP1B) and Body Composition Modification in Patients With Septic Shock (Coc-SEPP1B)
With a prevalence of more than 15% in ICU, septic shock today represents a real public health problem and remains the leading cause of mortality in ICU. Undernutrition is characterized by an alteration of the body composition and in particular by a loss of muscle mass. In intensive care, there are indirect elements suggesting a link between loss of muscle mass and prognosis.
Muscle mass results from a balance between the pathway of proteolysis and that of protein synthesis, depending on many factors, not one of the most important are insulin. The protein PTP1B (Protein Tyrosine Phosphatase 1B), by the dephosphorylation of its numerous substrates, constitutes an endogenous regulator of numerous intracellular signaling pathways, including that of insulin. PTP1B could play a role in the protein synthesis abnormalities observed during sepsis leading clinically to impaired body composition including muscle body mass. Therefore, we propose to study the association between PTP1B and loss of muscle mass in patients in sepsis in resuscitation.
The intestinal barrier plays an essential role in protecting against microbial luminal flora and the phenomenon of bacterial translocation. Zonulin is one of the major regulators of tight junctions, important actors in the intestinal barrier function. The increase in plasma zonulin levels, greater than 0.6 ng / mg, is directly correlated with increased intestinal permeability (16). However, elevation of plasma zonulin has never been evaluated in septic resuscitation patients. This is why we propose the evaluation of the association between plasma zonulin and the loss of muscle mass in these resuscitation patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Caroline LEMAITRE, MD
- Phone Number: +33 232886697
- Email: Caroline.Lemaitre@chu-rouen.fr
Study Contact Backup
- Name: Cécile POURCHER
- Phone Number: +33 232886697
- Email: cecile.pourcher@chu-rouen.fr
Study Locations
-
-
-
Rouen, France
- Recruiting
- ROUEN university hospital
-
Contact:
- Caroline LEMAITRE, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Septic shock or severe sepsis
- Age > 18 years old
- Affiliation to a social security system
- Information and consent. If patient cannot give his consent, an emergency consent will be sign by trusted person
- Contraception for woman, of childbearing age
Exclusion Criteria:
- Pregnancy or breastfeeding
- Prisoners
- Patient with pacemaker or defibrillator
- patient participating to a clinical trial with the same primary outcome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients With Septic Shock
Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PTP1B analysis
Time Frame: Day 1
|
1 PAXgene tube (2,5 ml) will be used.
RNA extraction will be done with a PAXgene Blood RNA System kit.
|
Day 1
|
Muscular composition
Time Frame: Day 1
|
Muscular composition will be measured by muscular echography with a 2B mode on D1 and D4 from the admission.T
|
Day 1
|
Muscular composition
Time Frame: Day 4
|
Muscular composition will be measured by muscular echography with a 2B mode on D1 and D4 from the admission.T
|
Day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intestinal permeability
Time Frame: Day 1
|
1 tube of 5 ml Aprotinin will be taken on D1 and D4 to determine the expression of plasma zonulin.
The concentration will be assayed by ELISA using a commercial kit (MyBiosource, USA).
|
Day 1
|
Intestinal permeability
Time Frame: Day 4
|
1 tube of 5 ml Aprotinin will be taken on D1 and D4 to determine the expression of plasma zonulin.
The concentration will be assayed by ELISA using a commercial kit (MyBiosource, USA).
|
Day 4
|
Body composition
Time Frame: Day 1
|
Body composition will be measured by impedancemetry on D1 and D4
|
Day 1
|
Body composition
Time Frame: Day 4
|
Body composition will be measured by impedancemetry on D1 and D4
|
Day 4
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Caroline LEMAITRE, ROUEN university hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016/108/HP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septic Shock
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityUnknown
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
Rennes University HospitalTerminated
Clinical Trials on Blood sampling
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisUnknownSepsis | Acute Circulatory FailureFrance
-
Royal Surrey County Hospital NHS Foundation TrustCompletedThyroid Carcinoma | Thyroid Cancer | Cancer of the Thyroid | Cancer of ThyroidUnited Kingdom
-
Institut CurieRecruitingProstate Cancer | Healthy DonorsFrance
-
University College, LondonUniversity College London HospitalsUnknownMultiple SclerosisUnited Kingdom
-
Centre Hospitalier Universitaire DijonRecruiting
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance